ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1841

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Abstract Number: 1842

Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
Abstract Number: 1843

Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response
Abstract Number: 1844

Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Abstract Number: 1845

Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Abstract Number: 1846

Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Abstract Number: 1847

Expression Levels of the ATP-Gated Ion Channel P2RX7 Do Not Predict T Cell Sensitivity to Extracellular ATP and NAD
Abstract Number: 1848

Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Abstract Number: 1849

Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Abstract Number: 1850

Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Abstract Number: 1851

Aberrant Tfh Cells Generated by Th17 Cell Plasticity in the Gut Promote Autoimmune Arthritis
Abstract Number: 1852

Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
Abstract Number: 1853

Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
Abstract Number: 1854

TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Abstract Number: 1855

Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].